Cancer Therapy: Success of the European Project ARGENT at Université Paris-Sud and at CNRS

Since March 2014, Sandrine LACOMBE, Professor at Paris-Sud University and head of the group "NanoHadron” at ISMO (Institute of Molecular Sciences at Orsay) is coordinating the ITN Marie-Curie project for excellence ARGENT on the theme of "Advanced Radiotherapy, Generated by Exploiting Nanoprocesses and Technologies".

The ARGENT project is an initial training program (ITN for Initial Training Network) funded by the Marie Curie Actions of the 7th Framework Programmes for Research and Technological Development of the European Union (FP7). ITNs are designed to train young early stage researchers, to get them to develop a scientific network approach and encourage them to open up to the company for the development of their careers.

Initiated in March 2014, the ARGENT program has also helped to recruit and fund 13 PhD students within a consortium of:

Academic partners

  1. Paris-Sud University (France) ;
  2. CNRS (France) ;
  3. CEA (France) ;
  4. Queen’s University (Belfast, UK);
  5. The Open University (Milton Keynes, UK);
  6. Technische Universidät Darmstadt (Darmstadt, Germany);
  7. CSIC (Madrid, Spain).

Industrial partners

  1. CheMatech (Dijon, France) ;
  2. QuantumWise (Copenhague, Denmark) ;
  3. NanoH (Lyon, France).

Associated partners

  1. Heidelberg Ionenstrahl Therapiezentrum (Heidelberg, Germany);
  2. Centre de lutte contre le cancer François Baclesse (Caen, France);
  3. Hospital Universitario Puerta de Hierro (Madrid, Spain);
  4. IBA (Louvain la Neuve, Belgium);
  5. Minerva (Londres, UK);
  6. MBN Research Center (Frankfurt am Main, Germany);

 

The 13 PhD students recruited for the ARGENT project

The main objective of this intersectorial and multidisciplinary ITN is to create a new generation of researchers and experts able to develop and propose to the society new tools and concepts for the improvement of cancer therapy treatments. The consortium aims to train a cohort of 13 PhDs (Early Stage Researchers – ESRs) to subsequently act as leaders and ambassadors in the field. The ITN ARGENT strategy relies:

  • on improving our understanding of the processes and mechanisms underlying radiation damage on a nanoscopic level,
  • on the application of the improved know-how in the production and development of functionalised nanodrugs to amplify the effects of medical beams and
  • on the developments of concepts and codes for clinical applications taking into account the new information.

In orther to go further:

Argent project : http://itn-argent.eu/